IMMUNE THROMBOCYTOPENIA
Clinical trials for IMMUNE THROMBOCYTOPENIA explained in plain language.
Never miss a new study
Get alerted when new IMMUNE THROMBOCYTOPENIA trials appear
Sign up with your email to follow new studies for IMMUNE THROMBOCYTOPENIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a cancer drug fix blood cell problems after transplant?
Disease control OngoingThis phase 2 trial tests whether isatuximab can help people whose blood cell counts stay low after a stem cell transplant for blood cancer. The study enrolls 12 adults whose disease is in remission but who have developed immune-related blood cell deficiencies. Participants receiv…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New pill could help people with low platelet disorder
Disease control OngoingThis phase 3 trial tests an oral drug called rilzabrutinib in 232 adults and adolescents with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. Participants receive either rilzabrutinib or a placebo…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE3 • Sponsor: Principia Biopharma, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New combo therapy shows promise for rare bleeding disorder
Disease control OngoingThis study tests whether adding diammonium glycyrrhizinate (a liver-protecting compound) to standard high-dose dexamethasone can improve platelet counts in adults newly diagnosed with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing b…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Shandong University • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New oral drug shows promise for Long-Term control of rare bleeding disorder
Disease control OngoingThis study is for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding and bruising. It tests the long-term safety and benefit of an oral drug called rilzabrutinib. Only 4 participants who already benefited fr…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Promising ITP drug trial pulled before it even started
Disease control TerminatedThis study was designed to test the safety and tolerability of a new drug called HMPL-523 (sovleplenib) in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding problems. The trial was withdrawn before enrolling any pa…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE1 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 26, 2026 18:23 UTC